Reactive oxygen species-activatable camptothecin polyprodrug based dextran enhances chemotherapy efficacy by damaging...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Anti-cancer nanomedicines (ANMs) face challenges like low drug loading, poor tumor accumulation, and weak permeability.
• Overcoming these barriers is crucial for enhancing chemotherapy efficacy.

Purpose of the Study:

• To develop a reactive oxygen species (ROS)-activatable anti-cancer nanomedicine (ANM) to address the limitations of current nanodrug delivery systems.
• To improve the therapeutic efficiency of chemotherapy by designing a smart nanomedicine responsive to the tumor microenvironment.

Main Methods:

• Synthesis of dextran-b-P(CPTMA-co-OEGMA) (DCPT) polyprodrug micelles encapsulating camptothecin (CPT).
• Evaluation of micelle disassembly and CPT release in response to high ROS levels characteristic of the tumor microenvironment.
• In vitro and in vivo studies to assess the anti-tumor efficacy and biosafety of the DCPT nanomedicine against 4T1 tumors.

Main Results:

• The DCPT polyprodrug micelles effectively disassembled in ROS-rich environments, leading to targeted CPT release.
• Significant inhibition of 4T1 tumor growth was observed with the DCPT nanomedicine.
• Studies demonstrated outstanding in vivo biosafety of the developed nanomedicine.

Conclusions:

• The developed ROS-activatable DCPT polyprodrug nanomedicine effectively overcomes common ANM limitations.
• This smart nanomedicine strategy shows superior therapeutic effects and biosafety, offering a promising approach for enhanced chemotherapy.
• Rational design of tumor microenvironment-responsive nanomedicines is a key strategy for improving cancer treatment outcomes.